Abstract Combined β-glucan with anti-tumor mAb therapy has demonstrated therapeutic efficacy in murine tumor models. The current study was designed to compare the therapeutic efficacy of various sources of β-glucans. Our studies demonstrated that yeast β-glucan, in combination with anti-tumor mAb, resulted in significantly smaller tumor burdens and achieved enhanced